Unisense FertiliTech A/S announces that the EmbryoScope(TM) Embryo Monitoring System and EmbryoSlide(TM) tray have received CE approval as class IIa medical devices for use in IVF. Unisense Fertilitech A/S also received the DS/EN ISO13485:2003 and AC:2007 quality system certificate for production, installation and servicing of IVF incubators and related accessories. Francesca Bahr, sales manager at Unisense FertiliTech A/S says, "the CE mark will allow us to market the instrument to Assisted Reproduction clinics across Europe, with the goal of improving embryo assessment and to facilitate the goal of elective single embryo transfer." During IVF treatment, multiple oocytes are removed from the patient and fertilized in-vitro.
St Helier Hospital, part of Epsom and St Helier University Hospitals NHS Trust, has recently celebrated the installation of a Symbia® T6 TruePoint SPECTâ CT from Siemens Healthcare. The unit combines a 6-slice CT with variable angle dual detector SPECT for rapid, accurate attenuation correction and precise localisation. St Helier Hospital is using the system to achieve rapid image acquisition for a wide range of procedures, including renal scans, brain scans and ventilation and perfusion scans. The dual angle detector makes it capable of improving image quality for even the most challenging of scans. Additionally the system places emphasis on patient comfort and can accommodate both paediatric and bariatric patients with ease.
A revolutionary new device which could save the lives of stroke patients has been developed by a University of Wolverhampton expert. Dr Gillian Pearce is one of the inventors of a blood clot removal device which could improve the survival rates of people who have suffered a stroke. There are 130, 000 strokes per year in the UK alone, and millions worldwide. The mainstay of treatment in the last three to four years has been to dissolve the clot using a drug called tPA (alteplase). But the drug is only licensed for use within three hours after the stroke has occurred and it cannot be given to everyone. An alternative to breaking down the clot is to remove it by mechanical extraction devices.
With rapid change taking place in the surgical environment as the range of interventional and minimally invasive procedures continues to expand, Royal Philips Electronics (AEX: PHI, NYSE: PHG) today announced the availability of the Veradius X-ray system. A mobile C-arm with a super thin, flat detector, Philips Veradius is designed to give the surgeon more flexibility and to improve patient care by streamlining workflow and improving image quality. The system also includes an additional monitor on the C-arm stand, enabling the operator to have an unobstructed view of the live image. Today's operating rooms are crowded with equipment and people, so it's not always easy to see team members and coordinate tasks.
ATS Medical Announces FDA Clearance And First Implant Of New ATS Simulus Semi-Rigid Annuloplasty Band
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced FDA clearance and the first implant of the ATS Simulus(R) Semi-Rigid Annuloplasty Band. The Simulus Semi-Rigid Annuloplasty Band was developed through the Company's collaboration with Genesee BioMedical and represents the latest addition to the expanding portfolio of valve repair products. Annuloplasty rings and bands are used in those cases where repair of a patient's heart valve is preferable to replacement of the valve. This new repair product has clinical applications that expand the existing therapeutic options for surgeons and their patients.
Abbott Receives CE Mark For Company's Next-Generation XIENCE PRIME TM Drug Eluting Stent, Advancing Leadership Position
Abbott announced that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter. "XIENCE PRIME leverages and will build upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials. The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area, " said Robert Hance, senior vice president, vascular, Abbott.